Conditions: Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma
Interventions: Drug: TNO155; Drug: TNO155 in combination with EGF816 (nazartinib)
Sponsors: Novartis Pharmaceuticals
Recruiting